Piramal Pharma Limited
All news and filings related to Piramal Pharma Limited.
View all news & filings- Medium impact
Piramal Pharma's UK Facility Receives 7 Observations in US FDA GMP Inspection
Piramal Pharma's UK facility inspection by the US FDA resulted in 7 observations related to practices, procedures, and documentation. The company is preparing a response to the FDA.
Read the summary - Low impact
Piramal Pharma to hold Institutional Investor Meetings in UK on Sep 29-30
Piramal Pharma Limited will conduct Institutional Investor Meetings in the United Kingdom on September 29th and 30th, 2026. These meetings are arranged by Avendus Spark Institutional Equities and will be held physically. Dates are subject to change.
Read the summary - Low impact
Piramal Pharma gets ESG Rating of 65 for FY26, up from 64
Piramal Pharma Limited received an ESG Rating of 65 for FY25-26 from NSE Sustainability Ratings and Analytics Limited, an improvement from its previous score of 64. The rating was voluntarily assigned by NSE Sustainability based on publicly available data.
Read the summary - Low impact
Piramal Pharma Releases Sustainability Report for FY2026
Piramal Pharma Limited released its Sustainability Report for FY2026. The report covers non-financial performance across its three business units and details progress in energy efficiency, renewable energy use, and water conservation. Key highlights include ₹8,869 crore in revenue and a 22.6% reduction in GHG emissions.
Read the summary - Medium impact
Piramal Pharma acquires additional 40.67% stake in Yapan Bio, making it a subsidiary
Piramal Pharma acquired an additional 40.67% stake in Yapan Bio for ₹76 crore, increasing its holding to 74% and making Yapan a subsidiary. Yapan Bio specializes in biologics manufacturing. This move integrates Yapan's capabilities into Piramal's service offerings.
Read the summary - Medium impact
Piramal Pharma to increase stake in Yapan Bio to 74%, making it a subsidiary
Piramal Pharma will acquire an additional 41% stake in Yapan Bio, increasing its total holding to approximately 74%. This will make Yapan Bio, a biologics CDMO, a subsidiary of Piramal Pharma. Final terms are yet to be determined.
Read the summary - Low impact
Piramal Pharma Schedules Investor Meetings with Ashwamedh, Jefferies, Kotak, Goldman Sachs
Piramal Pharma Limited will hold investor meetings in September 2026. Key events include Ashwamedh - Elara India Dialogue on Sep 2, Jefferies 5th India Forum on Sep 17, Kotak Healthcare Forum on Sep 18, and Goldman Sachs Global Healthcare CDMO Day on Sep 23-24.
Read the summary - Low impact
Piramal Pharma resumes operations at Ahmedabad facilities post-heavy rainfall
Piramal Pharma Limited has resumed operations at its Ahmedabad manufacturing facilities following a temporary suspension due to heavy rainfall. The company anticipates no material impact on its operations or financial performance and has initiated the insurance claim process.
Read the summary - Low impact
Piramal Pharma Limited Releases Transcript for Q1 FY27 Financial Results Conference Call
Piramal Pharma Limited released the transcript for its Q1 FY27 conference call on financial results. The call, held on July 30, 2026, covered unaudited standalone and consolidated results for the quarter ended June 30, 2026. The transcript is available on the company's website.
Read the summary - Medium impact
Piramal Pharma Ltd. 6th AGM: All Resolutions Passed with Requisite Majority
Piramal Pharma Limited's 6th AGM on July 30, 2026, saw all 10 resolutions passed with a requisite majority. Key approvals included adopting FY26 financial statements and re-appointing directors Peter DeYoung, Nathalie Leitch, Nandini Piramal, Sridhar Gorthi, and Peter Stevenson. The company also approved NCD issuance and subsidiary asset pledges.
Read the summary - Low impact
Piramal Pharma Q1 FY27 Concall Audio Recording Available
Piramal Pharma Limited has released the audio recording of its conference call concerning the financial results for the quarter ended June 30, 2026. The recording is available on the company's website.
Read the summary - High impact
Piramal Pharma Q1FY27 Revenue Up 17% to ₹2,270 Cr, EBITDA Soars 72%
Piramal Pharma Limited reported Q1 FY27 revenue of ₹2,270 crore, a 17% increase YoY. EBITDA surged 72% to ₹285 crore, with margins expanding to 12.5%. CDMO, CHG, and PCH businesses all showed robust growth. The company will host an earnings call on July 30, 2026.
Read the summary - Low impact
Piramal Pharma Grants Over 56 Lakh Stock Options Under Plan 2022
Piramal Pharma Limited approved the grant of 56,36,436 stock options under its Employee Stock Option and Incentive Plan 2022. Options are exercisable at ₹10 each. Vesting and exercise periods are staggered, with different timelines for US and non-US employees, extending up to July 2034 for some tranches.
Read the summary - Low impact
Piramal Pharma Suspends Ahmedabad Operations Due to Heavy Rainfall
Piramal Pharma has temporarily suspended operations at its Ahmedabad facilities due to heavy rainfall and flooding. The company is assessing the situation and expects operations to normalize in the coming days. The affected facilities account for less than 3% of consolidated revenues and are adequately insured.
Read the summary - Low impact
Piramal Pharma Limited schedules Q1 FY2027 Earnings Conference Call for July 30, 2026
Piramal Pharma Limited will host an investor and analyst conference call on July 30, 2026, from 9:30 AM to 10:15 AM IST to discuss its Q1 FY2027 results. Dial-in details for multiple regions are provided.
Read the summary - Medium impact
Piramal Pharma's US FDA Inspection Successfully Closed
Piramal Pharma Limited has successfully closed a US FDA inspection at its Sellersville, USA manufacturing facility. The company received an Establishment Inspection Report (EIR) from the US FDA, confirming the successful closure of the inspection.
Read the summary - Low impact
Piramal Pharma Ltd. to hold 6th AGM on July 30, 2026, via Video Conference
Piramal Pharma Limited will hold its 6th Annual General Meeting (AGM) on July 30, 2026, at 3:00 p.m. IST. The meeting will be conducted via Video Conference and Other Audio Visual Means. Shareholders will have access to e-voting facilities. Advertisements regarding the AGM and e-voting were published in Business Standard and Mumbai Lakshadweep.
Read the summary - Low impact
Piramal Pharma Releases FY26 Business Responsibility & Sustainability Report
Piramal Pharma Limited has released its Business Responsibility & Sustainability Report for FY 2025-26. The report covers PPL's operations, employee data, and CSR initiatives. It details material responsible business conduct issues and sets targets for emission reduction: 42% for Scope 1 & 2 by FY2030 and 25% for Scope 3 by FY2030.
Read the summary - Low impact
Piramal Pharma Ltd. Announces 6th AGM on July 30, 2026; Annual Report Released
Piramal Pharma Limited announced its 6th Annual General Meeting (AGM) scheduled for July 30, 2026. The company also released its Annual Report for FY 2025-26, including the Business Responsibility & Sustainability Report. Both documents are available on the company's website and will be sent to shareholders.
Read the summary - Low impact
Piramal Pharma Limited Promoter Group Reports No Share Encumbrance in FY26
Piramal Pharma Limited's Promoter Group has declared no encumbrance on the company's shares during FY2025-2026. This declaration is made as per SEBI (SAST) Regulations, 2011.
Read the summary - Low impact
Piramal Pharma Limited: Trading Window Closure for Q1 FY27 Results
Piramal Pharma Limited will close its trading window from July 1, 2026, for its designated persons and their relatives. The window will reopen 48 hours after the declaration of Q1 FY27 unaudited financial results. The date for the board meeting to approve these results will be announced later.
Read the summary - Low impact
Piramal Pharma Clarifies Share Price Surge, Cites Market Dynamics
Piramal Pharma Limited clarified that a recent news article about its share price surge did not contain material information requiring disclosure. The company stated that all information is public and it is unaware of any specific reason for the price movement, attributing it to market dynamics.
Read the summary - Low impact
Piramal Pharma Ltd. Announces 6th AGM on July 30, 2026
Piramal Pharma Limited will hold its 6th Annual General Meeting on July 30, 2026, at 3:00 p.m. IST via Video Conference. The company will distribute the AGM notice and FY2025-26 annual report electronically. Members are urged to update their KYC details for seamless communication and dividend claims.
Read the summary - Medium impact
Piramal Pharma's Dahej Site Closure Directions Permanently Revoked by GPCB
Piramal Pharma Limited's Dahej manufacturing site has had its closure directions permanently revoked by the Gujarat Pollution Control Board (GPCB). Operations at the site continue normally, with the company committed to environmental compliance.
Read the summary - Low impact
Piramal Pharma Ltd. Schedules Analyst/Institutional Investor Meetings from June 9-11, 2026
Piramal Pharma Limited will hold investor meetings from June 9-11, 2026. Meetings include Macquarie Equity Research, Motilal Oswal, and Choice Institutional Equities. These sessions will be conducted in both physical and virtual modes.
Read the summary - Low impact
Piramal Pharma to hold investor meetings from May 28 to June 12, 2026
Piramal Pharma Limited will engage with analysts and institutional investors through a series of meetings and conferences. The schedule spans from May 28, 2026, to June 12, 2026, with participation in events hosted by 360 ONE Capital, Bank of America, Citi, ICICI Securities, and Goldman Sachs in Mumbai.
Read the summary - Medium impact
Piramal Pharma's Digwal Facility Successfully Cleared by US FDA
Piramal Pharma Limited's Digwal, Telangana manufacturing facility has successfully closed its US FDA inspection. The US FDA has issued an Establishment Inspection Report (EIR) confirming the successful closure. This disclosure was made on May 18th, 2026.
Read the summary - Medium impact
Piramal Pharma's US Facility Receives 3 Observations from US FDA Inspection
Piramal Pharma's US facility in Sellersville received a Form-483 with three observations following a US FDA GMP inspection (May 4-8, 2026). Observations are recommended for VAI classification and do not relate to data integrity. The company is preparing a response.
Read the summary - Low impact
Piramal Pharma Ltd: Transcript of Concall on FY26 Audited Financial Results Released
Piramal Pharma Limited has released the transcript of its conference call discussing the audited financial results for the quarter and year ended March 31, 2026. The transcript is available on the company's website.
Read the summary - Low impact
Piramal Pharma Ltd. Updates Key Managerial Personnel Contact Details
Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel, including CFO Vivek Valsaraj and Company Secretary Maneesh Sharma, as per SEBI regulations for disclosure purposes.
Read the summary - Low impact
Piramal Pharma: Audio Recording of Q4 FY26 Results Conference Call Available
Piramal Pharma Limited has released the audio recording of its conference call discussing the audited financial results for the quarter and year ended March 31, 2026. The recording is available on the company's website.
Read the summary - Low impact
Piramal Pharma Q4FY26 Earnings Call Recording Available Online
Piramal Pharma Limited has made the audio recording of its conference call available online. The call, held on April 29, 2026, discussed the audited financial results for the quarter and year ended March 31, 2026.
Read the summary - Medium impact
Piramal Pharma Board Approves FY26 Audited Results; Reappoints Key Directors
Piramal Pharma Limited's Board approved audited FY26 financial results. Key appointments include Nandini Piramal as Executive Director & Chairperson and Peter DeYoung as Executive Director. Sridhar Gorthi and Peter Stevenson were re-appointed as Independent Directors. Maneesh Sharma joins as Company Secretary. Registered office address also changed.
Read the summary - Medium impact
Piramal Pharma Board Approves FY26 Audited Results; Reappoints Key Directors and KMP
Piramal Pharma Limited's Board approved audited FY26 results. Ms. Nandini Piramal reappointed as Executive Director & Chairperson for 3 years from April 1, 2027. Mr. Peter DeYoung reappointed as Executive Director for 3 years from October 6, 2026. Mr. Maneesh Sharma appointed Company Secretary & Compliance Officer from April 29, 2026. Registered office address change approved.
Read the summary - Medium impact
Piramal Pharma Board Approves FY26 Audited Results; Reappoints Key Directors
Piramal Pharma Limited's Board approved audited financial results for FY26 and Q4FY26. Key appointments include Ms. Nandini Piramal as Executive Director & Chairperson and Mr. Peter DeYoung as Executive Director, both re-appointed for three years. Mr. Maneesh Sharma appointed Company Secretary & Compliance Officer. Registered office address change approved.
Read the summary - Medium impact
Piramal Pharma Approves FY26 Audited Results; Reappoints Directors & New Company Secretary
Piramal Pharma approved audited FY26 results. Ms. Nandini Piramal reappointed as Executive Director & Chairperson for 3 years from April 1, 2027. Mr. Peter DeYoung reappointed as Executive Director for 3 years from October 6, 2026. Mr. Maneesh Sharma appointed Company Secretary from April 29, 2026. Registered office address change effective April 30, 2026.
Read the summary - Medium impact
Piramal Pharma Q4FY26 Results: Revenue Flat, PAT Declines Amidst Exceptional Item
Piramal Pharma Limited reported Q4FY26 consolidated revenue of ₹2,752 crore (flat YoY) and FY26 revenue of ₹8,869 crore (down 3% YoY). EBITDA declined 16% in Q4 to ₹507 crore. A significant ₹176 crore impairment loss led to a Q4 net loss of ₹9 crore. The company expects growth in FY27 driven by business momentum.
Read the summary - Medium impact
Piramal Pharma Q4FY26 Results: Revenue Flat, PAT Declines Amidst Impairment Loss
Piramal Pharma Limited reported Q4FY26 consolidated revenue of ₹2,752 crore (flat YoY) and FY26 revenue of ₹8,869 crore (down 3% YoY). Q4FY26 PAT was a loss of ₹9 crore after a ₹176 crore impairment charge. The company anticipates growth in FY27 driven by CDMO momentum, Kenalog acquisition, and consumer healthcare expansion. Net debt remained stable.
Read the summary - Medium impact
Piramal Pharma Approves FY26 Audited Results; Reappoints Key Directors
Piramal Pharma Limited approved audited standalone and consolidated financial results for FY26. Key appointments include re-appointment of Ms. Nandini Piramal as Chairperson and Mr. Peter DeYoung as Executive Director. Mr. Maneesh Sharma appointed Company Secretary. The registered office address will also change.
Read the summary - Medium impact
Piramal Pharma Board Approves FY26 Audited Results, Reappoints Key Directors
Piramal Pharma Limited's Board approved FY26 audited financial results. Ms. Nandini Piramal reappointed as Executive Director & Chairperson for 3 years from April 1, 2027. Mr. Peter DeYoung reappointed as Executive Director for 3 years from October 6, 2026. Mr. Sridhar Gorthi and Mr. Peter Stevenson reappointed as Independent Directors. Mr. Maneesh Sharma appointed as Company Secretary.
Read the summary - Medium impact
Piramal Pharma Board Approves FY26 Audited Results, Reappoints Key Directors
Piramal Pharma Limited approved its audited financial results for FY26. The company reported a profit after tax of ₹700.01 crore for the year ended March 31, 2026. Key appointments include Ms. Nandini Piramal as Executive Director & Chairperson and Mr. Maneesh Sharma as Company Secretary. Re-appointments of directors were also approved.
Read the summary - Low impact
Piramal Pharma Limited Schedules Q4 & FY26 Earnings Conference Call for April 29
Piramal Pharma Limited will host a conference call on April 29, 2026, to discuss its Q4 and full-year FY2026 results. The call is scheduled from 9:30 AM to 10:15 AM IST. Dial-in details for international participants are also available.
Read the summary - Medium impact
Piramal Pharma's US FDA Inspection Closes Successfully with VAI Classification
Piramal Pharma's US manufacturing facility in Lexington, USA, has successfully closed its US FDA inspection. The company received an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) classification, marking the closure.
Read the summary - Low impact
Piramal Pharma Limited Assigned ESG Rating of 64 by NSE
Piramal Pharma Limited received an ESG Rating of 64 for FY 2024-25 from NSE Sustainability Ratings and Analytics. This marks an improvement from its previous score of 61, reflecting the company's commitment to sustainability.
Read the summary - Medium impact
Piramal Pharma Completes Acquisition of Kenalog® Injectable Product
Piramal Pharma Limited has successfully completed the acquisition of Kenalog® and its associated brands from Bristol-Myers Squibb Company through its subsidiary Piramal Critical Care B.V. This move strengthens the company's Complex Hospital Generics portfolio and its presence in the US, Europe, and Asia Pacific markets.
Read the summary - Low impact
Piramal Pharma gets ESG Rating of 68.5 from SES ESG for FY25
Piramal Pharma Limited received an ESG Rating of 68.5 for FY 2024-25 from SES ESG Research. The rating was assigned voluntarily by SES ESG based on publicly available data. The company has published this information on its website.
Read the summary - Low impact
Piramal Pharma Schedules Investor Meeting on March 9, 2026
Piramal Pharma Limited will hold an investor meeting on March 9, 2026, in Mumbai with Investec India. The meeting will be conducted in person and may be subject to change.
Read the summary - Low impact
Piramal Pharma Ltd. updates KMP contact details for SEBI disclosures
Piramal Pharma Limited has updated the contact details for its Key Managerial Personnel (KMP) as per SEBI regulations. Mr. Vivek Valsaraj (CFO) and Ms. Pratibha Mishra (Interim Company Secretary) are designated for materiality assessments and disclosures to stock exchanges.
Read the summary - Medium impact
Piramal Pharma's Dahej Site Operations Resume Following GPCB Revocation
Piramal Pharma Limited's Dahej site operations are authorized to resume immediately following an interim revocation of closure directions by the Gujarat Pollution Control Board (GPCB). The company is working with GPCB to make these directions final.
Read the summary - Medium impact
Piramal Pharma's Digwal Facility Receives 4 Observations in US FDA Inspection
Piramal Pharma Limited's Digwal, Telangana facility was inspected by the US FDA from February 9-13, 2026. The inspection resulted in 4 observations related to procedural enhancements, classified as Voluntary Action Indicated (VAI) and not data integrity issues. PPL is preparing a response.
Read the summary
Model portfolios
Filings are the raw material. These are what SEBI-registered experts build from them.
- Stocks
Core Compounders
Companies that have already been through a downturn and came out still growing.
Moderate20 holdings3+ yearsView portfolio - Stocks
Udaan
Fast-growing, less-covered companies still early in their runway.
Aggressive29 holdings5+ yearsView portfolio - Stocks
Bharat Rising
Built around India's own shifts: capex, household savings, energy and consumption.
Moderate-Aggressive25 holdings3+ yearsView portfolio - Stocks
All-Terrain
One equity portfolio instead of three: large, mid and small cap in a single book.
Moderate-Aggressive34 holdings3+ yearsView portfolio